Peptides for Nerve Pain and Neuropathy: Top Options

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before considering any peptide therapy.

Neuropathy-related nerve pain affects millions worldwide, with diabetic peripheral neuropathy alone impacting up to 26% of diabetes patients severely enough to disrupt sleep and daily function. Traditional treatments often fall short, leaving patients searching for alternatives. Peptide therapies offer a fresh approach by targeting the biological mechanisms that drive nerve damage, inflammation, and pain signaling at the cellular level.

These specialized protein fragments work through multiple pathways—restoring nerve conduction, reducing inflammatory mediators, protecting neurons from oxidative stress, and blocking pain channels directly. Research focused on their activity spans from early animal models to Phase II clinical trials, with several peptides showing measurable improvements in sensory function and pain reduction.

Understanding Nerve Pain and Neuropathy

Neuropathic pain originates from damaged or dysfunctional nerves rather than tissue injury. In diabetic peripheral neuropathy (DPN), chronic hyperglycemia triggers oxidative stress, microvascular damage, and metabolic dysfunction that degrade nerve fibers over time. This manifests as burning, stabbing, or electric shock-like sensations, numbness, and heightened sensitivity to touch or temperature.

Nerve conduction velocity slows measurably in affected patients. Sensory thresholds shift—vibration perception becomes impaired, protective sensation diminishes, yet paradoxically pain responses amplify. The combination creates a challenging clinical picture where nerves simultaneously fail to transmit normal signals and fire excessive pain signals.

How Peptides Target Neuropathic Pain

Peptide therapies intervene at multiple points in the neuropathy cascade. Their mechanisms differ from conventional analgesics, which primarily block pain signals downstream. Peptides can restore nerve metabolism, reduce inflammatory cytokines, promote regeneration, and modulate ion channels directly on nociceptors.

Metabolic restoration 

C-peptide binds to cell surface receptors on neurons and endothelial cells, activating Na+/K+ ATPase and improving endoneurial blood flow. This addresses the metabolic deficits that underlie diabetic nerve dysfunction.

Receptor-mediated analgesia

Cortistatin activates somatostatin receptor 2 (sstr2) and the ghrelin receptor GHSR1, both of which are Gαi-coupled receptors. This inhibits adenylyl cyclase, reduces cAMP and PKA activity, and dampens calcium influx in dorsal root ganglion neurons—directly quieting nociceptor excitability.

Neurotrophic support 

Several peptides may boost brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which support axonal survival and regeneration after injury.

Ion channel blockade 

Targeted peptides inhibit CaV3.2 T-type calcium channels expressed on sensory neurons. These channels open during nerve injury and drive chronic pain signaling; blocking them selectively reduces pain without affecting normal sensation.

Top Peptides for Nerve Pain and Neuropathy

C-Peptide

C-peptide is co-secreted with insulin from pancreatic beta cells but is often overlooked in type 1 diabetes management. Unlike insulin, which regulates glucose, C-peptide exerts independent effects on nerve and vascular function. 

Preclinical models have demonstrated that C-peptide replacement corrects nerve conduction deficits, improves blood flow to nerves, and reverses structural abnormalities.

The most definitive human data comes from a 52-week Phase IIb trial testing PEGylated C-peptide (PEG-C-peptide) in 250 type 1 diabetes patients with mild-to-moderate peripheral neuropathy. Participants received weekly subcutaneous injections of 0.8 mg, 2.4 mg, or placebo.

The primary endpoint—sural nerve conduction velocity (SNCV)—improved in all groups by 2.1 to 2.5 m/s but showed no statistical difference between active treatment and placebo. However, vibration perception threshold (VPT) at the great toe improved progressively with PEG-C-peptide treatment. This sensory measure reflects the function of large myelinated fibers and showed dose-related benefits independent of conduction velocity changes.

Investigators noted that progressive sensation deficits define diabetic polyneuropathy, making the VPT findings clinically meaningful. Modified Toronto Clinical Neuropathy Scores (mTCNS) and 11-point pain ratings also trended toward improvement in treated patients.

Cortistatin

Cortistatin is a neuropeptide structurally related to somatostatin but with distinct receptor pharmacology. It acts through both sstr2 and the ghrelin receptor GHSR1, providing a dual mechanism of action that somatostatin lacks. 

Animal research demonstrates robust analgesic effects across multiple neuropathy models. In spared nerve injury (SNI), chronic constriction injury (CCI), partial sciatic nerve transection, and streptozotocin-induced diabetic neuropathy, cortistatin (2 µg administered peripherally or intrathecally) reduced mechanical allodynia, thermal hyperalgesia, and cold allodynia by 50-70%. Effects persisted for weeks after single treatments.

Mechanistic studies reveal that cortistatin desensitizes nociceptors through Gαi signaling, reduces levels of the pro-inflammatory cytokines TNF-α and IL-1β in nerve tissue, elevates neurotrophic BDNF and NGF levels, and promotes nerve fiber regeneration after transection. Mice lacking cortistatin showed worse pain outcomes, confirming it plays an endogenous protective role.

GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide and semaglutide were developed for diabetes management. They improve glycemic control by enhancing insulin secretion and slowing gastric emptying. GLP-1 receptors also appear on neurons, where agonist binding reduces oxidative stress and inflammation.

Clinical trials are currently testing liraglutide for DPN-related pain improvement. Another trial (which has since been withdrawn) was developed to examine N0750, a GLP-1RA analog, for pain reduction in diabetic neuropathy. The dual benefit was better glucose regulation plus direct neuroprotection, which makes this class potentially attractive for diabetic patients, who comprise the largest neuropathy population.

Up to 26% of DPN patients experience severe neuropathic pain linked to sleep disturbance and depression, creating substantial unmet need. GLP-1RAs may address both metabolic root causes and symptomatic pain.

CaV3.2 Channel-Targeting Peptides

Researchers at the Medical College of Wisconsin developed and patented peptides delivered via adeno-associated virus (AAV) to block CaV3.2 T-type calcium channels. These channels are upregulated in sensory neurons after nerve injury and contribute to ectopic pain signaling.

This form of peptide therapy selectively targets pain-transmitting neurons without affecting motor function or normal sensation. Animal studies showed pain reduction lasting months from a single treatment. The team plans human clinical trials, positioning this as a potential gene therapy approach to dealing with chronic nerve pain.

Comparison of Peptide Options

Peptide	Primary Mechanism	Clinical Stage	Key Finding	Administration
C-peptide	Na+/K+ ATPase activation, improved nerve blood flow	Phase IIb complete	VPT improvement in 52-week trial; SNCV non-significant	Weekly subcutaneous injection
Cortistatin	sstr2/GHSR1 agonism, Gαi inhibition	Preclinical	50-70% pain reduction in multiple animal models	Peripheral/intrathecal injection
GLP-1 agonists	GLP-1R activation, glycemic control, neuroprotection	Phase II/III ongoing	Symptom alleviation in DPN; dual metabolic benefit	Daily/weekly injection
CaV3.2 blockers	T-type calcium channel inhibition	Preclinical, patent granted	Months-long analgesia in rodent models	AAV gene therapy

Clinical Evidence and Study Results

The C-peptide phase IIb trial enrolled 250 participants across multiple sites, making it one of the largest peptide neuropathy studies. While the primary endpoint failed, the VPT secondary outcome showed dose-dependent improvement, with the 2.4 mg group demonstrating the clearest benefit. Researchers concluded that sensory transduction improvements may occur independently of conduction velocity changes and warrant further investigation.

Earlier C-peptide research established that replacement therapy corrects multiple functional and structural nerve abnormalities in animal models. The translation to humans remains incomplete, but the safety profile proved favorable across all doses tested.

GLP-1RA trials (NCT04137328, NCT06715462) remain ongoing. These studies build on observational data suggesting patients on GLP-1RAs for diabetes report fewer neuropathy symptoms compared to those on other glucose-lowering agents.

University of Illinois Chicago scientists are exploring a number of different peptides that may stop or reverse nerve cell degeneration. While early-stage, this research points toward regenerative rather than purely symptomatic approaches.

Safety & Contraindications

C-peptide demonstrated a favorable safety profile in the 52-week trial, with adverse events comparable between treatment and placebo groups. The PEGylated formulation reduces immunogenicity and allows weekly rather than continuous dosing. Patients with severe renal impairment may require dose adjustment, as C-peptide is renally cleared.

Cortistatin research remains preclinical in humans. Animal studies showed no major toxicity at therapeutic doses. The peptide’s natural occurrence in humans suggests good tolerability, but receptor-mediated effects on growth hormone and sleep cycles require monitoring.

GLP-1RAs carry known side effects including nausea, vomiting, and gastrointestinal discomfort, especially during titration. Rare cases of pancreatitis have been reported. They should be used cautiously in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

CaV3.2-targeting peptides delivered via AAV raise gene therapy considerations. While selective for sensory neurons, any genetic modification requires long-term safety monitoring. The MCW team has not yet published human safety data.

Patients considering any peptide therapy for neuropathy should work with clinicians experienced in peptide protocols. Most options remain investigational outside clinical trials.

Frequently Asked Questions

How long does it take for peptides to improve nerve pain?

Response times vary by peptide and delivery method. Cortistatin yielded effects within hours in animal studies, while C-peptide-associated improvements in vibration perception emerged gradually over 52 weeks. GLP-1RAs may provide pain relief within weeks as glycemic control stabilizes and direct neuroprotective effects accumulate.

Can peptides reverse existing nerve damage?

Some peptides appear to promote nerve regeneration in animal models. Cortistatin, for instance, increased nerve fiber density after transection, and C-peptide reversed structural abnormalities in diabetic rats. However, human data on true regeneration remains limited. Most evidence supports stabilization and functional improvement rather than complete reversal of chronic damage.

Are peptide treatments for neuropathy FDA-approved?

No peptides currently carry FDA approval specifically for neuropathic pain or peripheral neuropathy. C-peptide and cortistatin remain investigational. GLP-1RAs are approved for diabetes and obesity; their use for neuropathy-associated pain would be off-label. Clinical trials continue to build the evidence base needed for regulatory submissions.

Do these peptides work for non-diabetic neuropathy?

Cortistatin demonstrated benefits across nerve injury models unrelated to diabetes, including mechanical trauma and surgical transection. This suggests broader applicability. C-peptide’s mechanism of action centers on replacing a deficiency specific to type 1 diabetes, making it less relevant for other neuropathy causes. GLP-1RAs and CaV3.2 blockers may benefit non-diabetic neuropathy through inflammation reduction and pain channel blockade, but research to date has focused primarily on diabetic populations.

References

1. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab. 2000;278(5):E759-E768. https://diabetesjournals.org/diabetes/article/52/8/1976/12439/C-Peptide-and-Nerve-Function-in-Type-1-Diabetes
2. Long-acting C-peptide and neuropathy in type 1 diabetes: a 52-week randomized trial. Diabetes Care. 2016;39(4):596-602. https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1
3. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30(1):71-76. https://pubmed.ncbi.nlm.nih.gov/16443767/
4. Cortistatin reduces neuropathic pain in multiple rodent models through activation of somatostatin and ghrelin receptors. Korean J Pain. 2021;34(3):249-265. https://www.epain.org/journal/view.html?uid=1900&vmd=Full
5. Neuropeptide cortistatin attenuates inflammatory and neuropathic pain via somatostatin and ghrelin receptors. Front Cell Neurosci. 2021;15:695200. https://pmc.ncbi.nlm.nih.gov/articles/PMC8309056/
6. A study of long-acting C-peptide (CBX129801) in patients with type 1 diabetes mellitus and peripheral neuropathy. ClinicalTrials.gov NCT01681290. https://clinicaltrials.gov/study/NCT01681290
7. Liraglutide’s effect on diabetic peripheral neuropathy pain. ClinicalTrials.gov NCT04137328. https://clinicaltrials.gov/study/NCT04137328
8. A study to evaluate the efficacy and safety of N0750 in participants with diabetic peripheral neuropathy (DPN) pain. ClinicalTrials.gov NCT06715462. https://clinicaltrials.gov/study/NCT06715462
9. Diabetic peripheral neuropathic pain prevalence and clinical characteristics. ClinicalTrials.gov NCT01496365. https://clinicaltrials.gov/study/NCT01496365
10. Research team receives patent for new nerve block pain treatment. Medical College of Wisconsin. https://www.mcw.edu/mcwknowledge/mcw-stories/research-team-receives-patent-for-new-nerve-block-pain-treatment
11. Scientists think a peptide could stop, reverse damage to nerve cells. UIC Today. https://today.uic.edu/scientists-think-a-peptide-could-stop-reverse-damage-to-nerve-cells/